1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9823, H6Q-MC-JCBJ, PRELUDE, NCT00332202
|
|
2.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 45 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MCC-14787, H6Q-MC-S009, MCC-104545, LILLY-H6Q-MC-S009A, U01-CA-101222, NCT00387816
|
|
3.
|
Phase: Phase II
Type: Prevention
Status: Active
Age: 45 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10723, H6Q-MC-S009, NCT00414960
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10710, H6Q-MC-S020, NCT00415363
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9824, H6Q-MC-S028, NCT00451178
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10736, H6Q-MC-S023, NCT00451555
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11311, H6Q-MC-S032, NCT00466440
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 8671, H6Q-MC-S011, NCT00475644
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11491, H6Q-MC-S039, NCT00509821
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-08-C-0015, 08-C-0015, NCI-H6Q-MC-S033, NCT00559923
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10534, H6Q-MC-S064, NCT00612586
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1807, E1807, NCT00685633
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11531, H6Q-MC-S061, NCT00709995
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11481, H6Q-MC-S042, NCT00718419
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11496, H6Q-MC-JCCB, NCT00744991
|
|
16.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: NCI-07-C-0053, LILLY-NCI-07-C-0053, NCT00438997
|
|
17.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: PBTC-023, PBTC-023, NCT00503724
|
|
18.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: JHOC-J0688, H6Q-MC-S029, JHOC-J0688, JHOC-NA_00004943, NCT00550927
|
